DaVita, a Denver-based independent medical group and kidney care services provider, entered into a six-year supply agreement with Thousand Oaks, Calif.-based Amgen.
DaVita has committed to meet minimum required purchasing volumes of Amgen's kidney drugs Epogen and Aranesp. In return, the company will receive discounted pricing and rebates on the drugs.
The deal replaces prior agreements between the two parties set to expire in 2018.
More articles on supply chain:
Judge orders Sanofi, Regeneron's cholesterol drug off the market following patent dispute
10 medical device trends for 2017
Director of supply chain named one of best jobs in America by CNNMoney